Cost–utility analysis of sotagliflozin for heart failure patients with diabetes in China

Documenti analoghi

• Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure
  di: Juliane Rascher, et al.
  Pubblicazione: (2024)
• Drug‐induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis
  di: Qingfeng He, et al.
  Pubblicazione: (2024)
• Predicting potassium trajectories for risk monitoring in outpatients with heart failure, diabetes mellitus or chronic kidney disease
  di: Camilo Scherkl, et al.
  Pubblicazione: (2025)
• Propafenone‐ vs . amiodarone‐associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure
  di: Yi‐Cheng Lin, et al.
  Pubblicazione: (2025)
• Population pharmacokinetic analysis of the interaction of digoxin with N‐desethylamiodarone in patients with atrial fibrillation and heart failure
  di: Toshinori Hirai, et al.
  Pubblicazione: (2025)